Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life: The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

OPERA Study Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP
OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind73
Udgave nummer4
Sider (fra-til)654-661
Antal sider8
ISSN0003-4967
DOI
StatusUdgivet - 2014

Fingeraftryk

Triamcinolone
Methotrexate
Joints
Placebos
Quality of Life
Research Personnel
Clinical Trials
Adalimumab

Citer dette

@article{bb03d3dfe07a4831b677972e863ceb5f,
title = "Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life: The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial",
abstract = "OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP",
author = "Kim Horslev-Petersen and Hetland, {M. L.} and Peter Junker and J. Podenphant and Torkell Ellingsen and P. Ahlquist and H. Lindegaard and A. Linauskas and A. Schlemmer and Dam, {Mette Yde} and Ib Hansen and Horn, {Hans Christian} and Ammitzboll, {Christian Gytz} and Anette J{\o}rgensen and Krintel, {S. B.} and Johnny Raun and Johansen, {Julia Sidenius} and Mikkel {\O}stergaard and Kristian Stengaard-Pedersen and {OPERA Study Group}",
year = "2014",
doi = "10.1136/annrheumdis-2012-202735",
language = "English",
volume = "73",
pages = "654--661",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "B M J Group",
number = "4",

}

TY - JOUR

T1 - Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life

T2 - The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

AU - Horslev-Petersen, Kim

AU - Hetland, M. L.

AU - Junker, Peter

AU - Podenphant, J.

AU - Ellingsen, Torkell

AU - Ahlquist, P.

AU - Lindegaard, H.

AU - Linauskas, A.

AU - Schlemmer, A.

AU - Dam, Mette Yde

AU - Hansen, Ib

AU - Horn, Hans Christian

AU - Ammitzboll, Christian Gytz

AU - Jørgensen, Anette

AU - Krintel, S. B.

AU - Raun, Johnny

AU - Johansen, Julia Sidenius

AU - Østergaard, Mikkel

AU - Stengaard-Pedersen, Kristian

AU - OPERA Study Group

PY - 2014

Y1 - 2014

N2 - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP

AB - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP

U2 - 10.1136/annrheumdis-2012-202735

DO - 10.1136/annrheumdis-2012-202735

M3 - Journal article

C2 - 23434570

VL - 73

SP - 654

EP - 661

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -